Advertisement

Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
Posted: 10/21/2022 | By: Larry Rosenberg, PhD

Question 2 of 5

A subgroup analysis of the phase III ALSYMPCA trial indicated that in patients with symptomatic metastatic CRPC (mCRPC), Ra-223 treatment provides clinical benefit in which subgroup?

Choose 1

A
Only in patients older than 65 years of age
B
Only in those who had received prior taxane therapy
C
Only in those with no prior androgen receptor–targeted therapy
D
Regardless of prior taxane or androgen receptor–targeted therapy

CategoriesView All Quizzes

Tumor Type



Conference Coverage



Additional Topics